Clinical Trials - Patient

Clinical Trials - Patient

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of First Line Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer with Immunobiomarker Signature-Driven Analysis (EA5163)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Ibrutinib Plus Obinutuzumab vs Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (A041702) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Nivolumab with Ipilimumab or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1/L1 Agent (S1616) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized STudy of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chonic Myeloid Leukemia; Patients with Molecular Evidence of Disease (S1712) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum Resistant or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer (GY005) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer with HER2 Amplification (S1613) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial Comparing Adjuvant Pembrolizumab vs Standard of Care Observation in Completely Resected Merkel Cell Carcinoma of Skin (EA6174) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma (EA6134) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel vs Gemcitabine and Cisplatin in Newly Diagnosed Advanced Biliary Tract Cancers (S1815) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Paclitaxel and Carboplatin vs Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-naive Sex Cord Stromal Tumors of the Ovary (GOG0264) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial of Pelvic Radiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic Only Recurrence of Carcinoma of the Uterine Corpus (GOG-0238)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine versus Gemcitabine alone in Patients with Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment (CT4006) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Phase III Study of Pembrolizumab vs Placebo in Combination with NeoAdjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High Risk Early Stage Hormone Positive, HER2 Negative Breast Cancer (MK3475-756) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Placebo Controlled Pilot Study of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced NonSmall Cell Lung Cancer (A221504)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Placebo Controlled Study Evaluating teh Efficacy and Safety of Copanlisib in Combination with Rituximab In Relapsed Indolent B-Cell NonHodgkins Lymphoma (CHRONOS-3) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Placebo Controlled Study of Talapzoparib with Enzalutamide in Metastatic Castration Resistant Prostate Cancer (C3441021) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Study of Cabozantinib vs Placebo in Patients with Advanced Neuroendocrine or Carcinoid Tumors after Progression on Everolimus (A021602) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double Blind Trial of Tucatinib or Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Subjects with Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer (SGNTUC-016) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Double-Blind Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First Line HER-2 Positive Metastatic Breast Cancer (BR004) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Multicenter Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy (17058) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer (INTR@PID) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Randomized, Placebo-Controlled, Double Blind Study of Adjuvant Cemiplimab vs Placebo After Surgery and Radiation Therapy In Patients with High Risk Cutaneous Squamous Cell Carcinoma (R2810-ONC-1788)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Safety and Efficacy Study of XERMELO Plus First Line Chemotherapy in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (NA) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
A Sequential 2 Arm Open Label Study to Evaluate teh Effects of Encorafenib in Combination with Binimetinib In Patients with BRAF V600 Mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Array-818-103) I
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members